Takeda's subcutaneous vedolizumab nabs CHMP nod for maintenance of ulcerative colitis and Crohn's

Takedas subcutaneous formulation of its gutselective biologic vedolizumab has secured recommendation from the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP it has emerged which advocated for its use as a maintenance tre...